Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Barrie D. Evans"'
Autor:
V J Harvey, Anne Lethaby, Vijay Singh, Paul Thompson, Barbara H. Mason, Ian M. Holdaway, Barrie D. Evans
Publikováno v:
ANZ Journal of Surgery. 73:905-908
Background: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) appear to influence the growth of breast cancer cells in vitro, and epidemiological studies suggest higher serum IGF-I levels increase the risk of breast cancer. IGF
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2245f45090a1995b225777123ebaace8
https://doi.org/10.1046/j.1445-2197.2003.02817.x
https://doi.org/10.1046/j.1445-2197.2003.02817.x
Autor:
Paul Thompson, Michael R. McCrystal, David Porter, Bruce C. Baguley, V J Harvey, Barrie D. Evans
Publikováno v:
Cancer Chemotherapy and Pharmacology. 44:39-44
N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA) is a new DNA-intercalating drug with a dual mode of cytotoxic action that is thought to involve topoisomerases I and II. On the basis of novelty of action and promising preclinical activity agai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c9aa741ce3d92ca52ab876d8fd052ec
https://doi.org/10.1007/s002800050942
https://doi.org/10.1007/s002800050942
Autor:
James W. Paxton, Philip Kestell, Michael R. McCrystal, Bruce C. Baguley, Ranjith S.K.A. Gamage, Barrie D. Evans, Ingrid C. Dunlop
Publikováno v:
Cancer Chemotherapy and Pharmacology. 44:45-50
DACA [N-[2-(dimethylamino)ethyl]acridine-4-carboxamide] is an acridine derivative with high activity against solid tumours in mice and a dual mode of cytotoxic action involving topoisomerases I and II. The plasma pharmacokinetics of DACA were studied
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf3cf6a43c59fffd82205903788e1636
https://doi.org/10.1007/s002800050943
https://doi.org/10.1007/s002800050943
Autor:
Ian M, Holdaway, Barbara H, Mason, Anne E, Lethaby, Vijay, Singh, Vernon J, Harvey, Paul I, Thompson, Barrie D, Evans
Publikováno v:
ANZ journal of surgery. 73(11)
Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) appear to influence the growth of breast cancer cells in vitro, and epidemiological studies suggest higher serum IGF-I levels increase the risk of breast cancer. IGF-I and IGFBP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a7fc7f8e673d0386dbb8ad97505d77ab
https://pubmed.ncbi.nlm.nih.gov/14616567
https://pubmed.ncbi.nlm.nih.gov/14616567
Autor:
Michael R. McCrystal, James W. Paxton, Iain G. C. Robertson, Philip C. Schofield, Philip Kestell, Barrie D. Evans, Bruce C. Baguley
Publikováno v:
Cancer chemotherapy and pharmacology. 44(1)
N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA) is an experimental antitumour agent that has just completed phase I clinical trials in New Zealand and the United Kingdom. Urine (0–72 h) was analysed from 20 patients receiving DACA infused o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dc1a9fac87ebc9cc81fcd5148d0d531
https://pubmed.ncbi.nlm.nih.gov/10367749
https://pubmed.ncbi.nlm.nih.gov/10367749
Autor:
Paul Mitchell, Carol Stone, Patricia Melville, Dora Mak, Paul Thompson, Barrie D. Evans, Christopher Ellis, Vernon Harvey
Publikováno v:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 1(4)
At Auckland hospital there is a combined medical and nursing preparation for patients receiving cytotoxic chemotherapy. The aim of the current study was to assess whether patients felt that this combined approach had prepared them adequately for chem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ec3c167a160283ee1870830da05877b
https://pubmed.ncbi.nlm.nih.gov/8193883
https://pubmed.ncbi.nlm.nih.gov/8193883
Publikováno v:
Cancer treatment reviews. 10
Twenty-seven patients, 16 with limited disease and 11 with extensive disease have so far been entered into the study. Conventional chemotherapy consisted of VP-16 100 mg/m 2 i.v. days I-3, adriamycin 40 mg/m 2 day 1 and vincristine 1.4 mg/m 2 day 1 (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b978be356d9c0bed02e88d2eb9ea5c40
https://pubmed.ncbi.nlm.nih.gov/6313192
https://pubmed.ncbi.nlm.nih.gov/6313192
Publikováno v:
Cancer chemotherapy and pharmacology. 21(1)
Response to second-line therapy in relapsing patients with small cell lung carcinoma (SCLC) is often claimed to be evidence in favour of non-cross resistance. Fifteen patients with SCLC who had relapsed off treatment after responding to initial first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b80e271c501015dc8192b86e42f3de7b
https://pubmed.ncbi.nlm.nih.gov/2830043
https://pubmed.ncbi.nlm.nih.gov/2830043
Autor:
Ian E. Smith, Barrie D. Evans
Publikováno v:
Cancer treatment reviews. 12
Carboplatin, a cisplatin analogue without significant nephrotoxicity, was used as a single agent in the treatment of 56 patients with small cell lung carcinoma at a dose of 300–400 mg/m 2 i.v. monthly. Twenty-three patients (41%) achieved a respons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5df3cbb2ed0bac54094fc2b7ef4b0846
https://pubmed.ncbi.nlm.nih.gov/3002624
https://pubmed.ncbi.nlm.nih.gov/3002624